Reversing the Irreversible: NurExone Biologic’s (NRXBF) Regenerative Exosome Therapy for Spinal Cord and Nerve Injuries

In this episode of WTR Healthcare Happenings, Dr. Lior Shaltiel, CEO of NurExone Biologic (TSXV: NRX | OTCQB: NRXBF), and Yoram Drucker, Founder, VP of Business Development, and Active Chairman, join host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, along with WTR Senior Equity Research Analyst Robert Sassoon.

The conversation explores NurExone’s groundbreaking exosome-based ExoTherapy platform and its lead candidate ExoPTEN, designed to regenerate damaged neurons following spinal cord and optic nerve injuries—two massive unmet medical markets. Shaltiel and Drucker discuss the company’s remarkable preclinical data showing functional recovery in up to 100% of animal models, the mechanism of action behind their siRNA-loaded exosomes, and why their cell-free, off-the-shelf therapy may become a game-changer for central nervous system repair.

They also highlight NurExone’s U.S. manufacturing subsidiary, ExoTop, expected to begin generating revenue in 2026, and share updates on regulatory milestones, cash position, and plans to uplist to a U.S. national exchange.